Pediatric Urology Academy is an evidence-based educational podcast hosted by Amin Afrasiabi, MD, Pediatric Urologist. Each episode explores pediatric urology through clinical cases, landmark studies, practical decision-making, surgical principles, and emerging research. Topics include posterior urethral valves, vesicoureteral reflux, hydronephrosis, UPJO, megaureter, neurogenic bladder, hypospadias, disorders of sexual development, pediatric stone disease, and reconstructive surgery. Designed for pediatric urologists, urologists, residents, fellows, and healthcare professionals worldwide.
Pitch Analysis
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
31%
Guest openness
Selective
80/100
Required Score
Sign up to generate a grounded pitch for Pediatric Urology Academy.
Pediatric Urology Academy is a health podcast hosted by Amin Afrasiabi, MD, Pediatric Urologist, with 60 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.
About the host
Amin Afrasiabi, MD, Pediatric Urologist hosts Pediatric Urology Academy, a health show with 60 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #17
Cryptorchidism and Cancer: What Does Orchiopexy Change—and What Does It Not?
Sep 17, 20264 minS5
Cryptorchidism increases the lifetime risk of testicular germ-cell cancer. But does orchiopexy actually prevent malignancy—or does it mainly reduce risk and make the testis easier to examine? In the Season 5 finale of Pediatric Urology Academy, we examine the relationship between undescended testes, testicular dysgenesis, germ-cell neoplasia in situ, timing of orchiopexy, and later testicular cancer. We explore why the malignancy risk may reflect both prolonged abnormal testicular position and intrinsic developmental abnormalities that existed before surgery. The episode critically examines the evidence behind prepubertal orchiopexy, including the important distinction between reducing cancer risk and normalizing it. We also discuss laterality, the role of the contralateral descended testis, why routine postoperative ultrasound surveillance is not supported, and the more difficult problem of the postpubertal undescended testis. When should an adolescent testis still be preserved? When does orchidectomy become more rational? And how should fertility, endocrine function, testicular location, and contralateral testicular health change that decision? Central principle: Orchiopexy changes environment and accessibility. It does not erase the biology that made the testis abnormal. Pediatric Urology Academy — advanced clinical reasoning and surgical judgment in pediatric urology.
Cryptorchidism and Fertility: What Does Orchiopexy Actually Rescue?
Sep 16, 20264 minS5
If orchiopexy is performed early, can we tell parents that fertility has been preserved? Not quite. In Season 5, Episode 16 of Pediatric Urology Academy, we examine what orchiopexy actually changes in the fertility pathway—and where the evidence becomes much less certain. We separate five outcomes that are often treated as interchangeable but are not: testicular volume, germ-cell histology, inhibin B and FSH, semen quality, and eventual paternity. Early orchiopexy is associated with better testicular growth and more favorable histologic and endocrine surrogate markers. But those findings do not automatically translate into normal adult fertility. The distinction between unilateral and bilateral cryptorchidism is critical. After unilateral disease, reproductive function may remain relatively well preserved because the contralateral testis can compensate. Bilateral cryptorchidism carries a substantially greater fertility burden and deserves different counseling. We also examine the evidence linking delayed surgery with later assisted reproductive technology use, the limitations of testicular volume as a fertility surrogate, and the controversial role of postoperative hormonal treatment. The central clinical message is: Early orchiopexy preserves reproductive opportunity. It does not guarantee future fertility. Pediatric Urology Academy — advanced clinical reasoning and surgical judgment in pediatric urology.
Redo Orchiopexy: How Do You Rescue a Testis After the First Operation Failed?
Sep 15, 20265 minS5
A testis has re-ascended after orchiopexy. The second operation is not simply a repeat of the first. In Season 5, Episode 15 of Pediatric Urology Academy, we examine redo orchiopexy as a problem of altered anatomy, scar, vascular vulnerability, and—most importantly—understanding why the original operation failed. Was proximal mobilization inadequate? Was the testis fixed under tension? Is there persistent tethering? Has scar contraction shortened the effective cord? Or was the original “success” actually a high, unstable position? We discuss preoperative confirmation of true re-ascent, assessment of testicular viability, safe dissection in a previously operated groin, protection of the vas and vessels, proximal mobilization, route modification, selective Prentiss-type medialization, and when laparoscopy can provide useful additional length. The critical intraoperative question is when to stop dissecting. If further scar dissection threatens the vas or vascular pedicle without producing meaningful length, the strategy should change rather than the traction increase. A successful redo is not a testis that merely reaches the scrotum during surgery. It is a viable testis that remains there afterward without tension. Central principle: In redo orchiopexy, scar is not the enemy. Unrecognized mechanism is. Pediatric Urology Academy — advanced clinical reasoning and surgical judgment in pediatric urology.
Shehata Versus Fowler-Stephens: Which Testis Should Get Which Operation?
Sep 14, 20264 minS5
A high intra-abdominal testis still cannot reach the dependent scrotum after complete vessel-preserving mobilization. Should you preserve the native testicular vessels with staged traction—or divide them and deliberately rely on collateral circulation? In Season 5, Episode 14 of Pediatric Urology Academy, we compare the Shehata traction technique with staged Fowler-Stephens orchiopexy from the perspective that matters most: patient selection. Shehata attempts to preserve the original vascular supply by gradually lengthening the spermatic pedicle. Fowler-Stephens accepts the short-pedicle problem and changes the vascular strategy, relying on deferential and cremasteric collateral circulation. Recent comparative studies and meta-analyses suggest encouraging outcomes with Shehata, including lower reported atrophy in some pooled analyses. But the evidence remains limited by small studies, selection bias, inconsistent definitions of high intra-abdominal testis, and short follow-up. The important question is therefore not simply which operation has the higher reported success rate. It is which biological compromise the individual testis can tolerate. Central principle: Shehata asks the pedicle to adapt. Fowler-Stephens asks the collateral circulation to take over.
Fowler-Stephens Orchiopexy: What Actually Keeps the Testis Alive?
Sep 13, 20264 minS5
A high intra-abdominal testis cannot reach the scrotum on its native vessels. You divide the testicular vessels. What keeps the testis alive now? In Season 5, Episode 13 of Pediatric Urology Academy, we examine Fowler-Stephens orchiopexy as a vascular operation rather than simply a maneuver for gaining length. After division of the primary testicular vessels, survival depends on collateral perfusion through the deferential and cremasteric vascular networks and their anastomoses around the epididymis and lower pole. We explore why staging may matter, the physiological rationale for one-stage versus two-stage Fowler-Stephens, the importance of preserving tissue around the vas, the possible value of gubernacular preservation, and how excessive dissection during the second stage can jeopardize the very collateral circulation the operation depends upon. The episode also addresses a critical misconception: Dividing the spermatic vessels does not create length. It removes the vascular constraint on descent and deliberately transfers dependence to another blood-supply network. The operative challenge is therefore not merely bringing the testis down. It is gaining adequate mobility while preserving enough collateral circulation for the testis to survive. Central principle: Fowler-Stephens is not simply vessel division for length. It is a deliberate conversion from one vascular system to another. Pediatric Urology Academy — advanced clinical reasoning and surgical judgment in pediatric urology.
Every question we get asked before someone starts their trial.
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
What is the difference between Founder Solo and Founder Pro?
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
How do agency tiers work?
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
What is a talent profile?
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Can I switch plans later?
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Do you offer a free trial?
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
What happens if I cancel?
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Is the 20% annual discount automatic?
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
What if I have more than 50 profiles or 20 clients?
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.